ClinicalTrials.gg
RecruitingNCT06790914Updated Jan 24, 2025

Investigation on the Status Quo of Hyperalgesia in Patients After Thoracoscopic Operation and Study on the Effect of Intraoperative Intervention

An interventional study of Flurbiprofen axidate combined with noise-cancelling headphones music and Flurbiprofen axidate combined with noise-cancelling headphones in Thoracoscopic Surgery and Hyperalgesia, sponsored by Fujian Medical University Union Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-24.

Sponsored by Fujian Medical University Union Hospital · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Registered 8 months after the study started (first participant enrolled Mar 2024, registered Nov 2024).
  • Started Mar 2024; still recruiting 2 years 7 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

To explore the status quo and influencing factors of hyperpain in patients after thoracoscopic surgery, and to explore the effect of earphone sound isolation during combined operation of flurbiprofen axidate and binaural beat music played by earphone during combined operation on the intervention of hyperpain after thoracoscopic surgery.

Read the detailed description

In this study, patients undergoing thoracoscopy radical lung cancer surgery in Union Hospital Affiliated to Fujian Medical University were selected for A randomized controlled trial. Patients were selected according to the inclusion and exclusion criteria, and the patients were randomly divided into group A of flurbiprofen axidate combined with noise-canceling headset music test, group B of flurbiprofen axidate combined with noise-canceling headset test, and the control group for intraoperative intervention study.

02

Conditions studied

  • Thoracoscopic Surgery
  • Hyperalgesia

Browse trials for

03

In context

Hyperalgesia

166 studies on the registry are indexed under Hyperalgesia; 14 are open to participants now.

This study's planned enrollment of 90 is above the median of 50 across 142 interventional studies indexed under Hyperalgesia.

Browse Hyperalgesia studies →

Lead sponsor

Fujian Medical University Union Hospital is the lead sponsor of 109 studies on the registry; 79 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients selected by the same group of surgeons to perform thoracoscopic three-hole radical resection of lung cancer
  • Patients ≥18 years old, able to communicate effectively and cooperate with the completion of clinical trials
  • I-III
  • Normal hearing; Patients who have not participated in other trials in the last two months

Exclusion criteria

Exclusion Criteria:

  • Previous history of thoracic surgery
  • History of chronic pain and any intake of analgesics 48 hours before surgery; ● Have a history of mental illness, or have taken psychiatric drugs or received psychological treatment in the past six months
  • Deformity of the auricle, inability to wear headphones, and failure to cooperate with this study for any reason
  • suffering from concurrent severe organ system diseases and hearing impairment
  • Incomplete data collection
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Flurbiprofen axidate combined with noise-cancelling headphones music

    30min before induction of general anesthesia, flurbiprofen axidate 50mg+ normal saline 50ml at 60 drops /min; After general anesthesia induction, noise-cancelling headphones (Sony WH-1000XM3) were fully covered with both ears, and MP3 (GoGear, Philips) was connected to play music continuously until the headphones were removed after the operation.

    Behavioral: Flurbiprofen axidate combined with noise-cancelling headphones music

  • Experimental
    flurbiprofen axidate combined with noise-cancelling earphone

    30min before induction of general anesthesia, flurbiprofen axidate 50mg+ normal saline 50ml at 60 drops /min; After induction of general anesthesia, noise-cancelling headphones (Sony WH-1000XM3) were applied to cover both ears completely until the headphones were removed at the end of the procedure.

    Behavioral: Flurbiprofen axidate combined with noise-cancelling headphones

  • Placebo comparator
    Flurbiprofen exate on a drip

    30min before induction of general anesthesia, flurbiprofen axidate 50mg+ normal saline at 60 drops /min.

    Other: Flurbiprofen exate on a drip

Interventions

  • BehavioralFlurbiprofen axidate combined with noise-cancelling headphones music

    30min before induction of general anesthesia, flurbiprofen axidate 50mg+ normal saline 50ml at 60 drops /min; After general anesthesia induction, noise-cancelling headphones (Sony WH-1000XM3) were fully covered with both ears, and MP3 (GoGear, Philips) was connected to play music continuously until the headphones were removed after the operation.

  • BehavioralFlurbiprofen axidate combined with noise-cancelling headphones

    30min before induction of general anesthesia, flurbiprofen axidate 50mg+ normal saline 50ml at 60 drops /min; After induction of general anesthesia, noise-cancelling headphones (Sony WH-1000XM3) were applied to cover both ears completely until the headphones were removed at the end of the procedure.

  • OtherFlurbiprofen exate on a drip

    30min before induction of general anesthesia, flurbiprofen axidate 50mg+ normal saline at 60 drops /min.

06

What researchers measure

Primary outcomes

  1. The mechanical pain threshold of the medial forearm of the healthy side and the incision area

    Von Frey cilia were used to measure the pain threshold of the patients. There were 20 kinds of Von Frey cilia intensity, and the corresponding mechanical pain threshold ranges from 0.008 to 300g. Hyperalgesia occurs when values around the incision and/or in the non-dominant forearm are reduced after surgery compared to before surgery.

    Time frame: The first day before surgery, the first day after surgery, and the second day after surgery

Secondary outcomes

  1. Numerical Rating Scale(NRS)

    NRS is a number from 0 to 10 used instead of words to indicate the severity of pain. Score 0 was no pain; 1 to 3 are classified as mild pain, tolerable, and sleep is not affected; 4 to 6 are classified as moderate pain, which begins to affect the patient's sleep and requires the use of painkillers; 7 \~ 9 is classified as severe pain, patients with unbearable pain, affect appetite, sleep is seriously disturbed, autonomic nerve is disturbed; 10 is severe pain.

    Time frame: The first day before surgery, the first day after surgery, and the second day after surgery

  2. The first time additional analgesics (NRS≥4) are required after surgery

    The first time additional analgesics (NRS≥4) are required after surgery

    Time frame: Within one day of surgery

  3. The effective number of PCA pump compressions within 48 h after surgery

    The effective number of PCA pump compressions within 48 h after surgery

    Time frame: Within two days of surgery

  4. Total intraoperative use of remifentanil, sevoflurane, and vasoactive agents.

    Total intraoperative use of remifentanil, sevoflurane, and vasoactive agents.

    Time frame: Within one day of surgery

  5. The number of adverse reactions (nausea, vomiting, hypotension, etc.) within 48 hours after surgery

    The number of adverse reactions (nausea, vomiting, hypotension, etc.) within 48 hours after surgery

    Time frame: Within two days of surgery

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Mar 2025, 12 months after the start.

Of 27 non-industry interventional studies with no phase under Hyperalgesia, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 32. This study's planned 12 months is close to that.

Counting every sponsor, half of 27 studies reached it within 11 months; a quarter within 4 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2024
First posted
Jan 24, 2025
StartActual
Mar 17, 2024
Primary completionEst.
Mar 17, 2025
CompletionEst.
Mar 17, 2025
Last update
Jan 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06790914
Responsible party
Sponsor
First posted
Jan 24, 2025
Start date
Mar 17, 2024
Primary completion
Mar 17, 2025 (estimated)
Completion
Mar 17, 2025 (estimated)
Last update
Jan 24, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion